Early observations and pilot data that first suggested a new direction
For decades, moderate-to-severe atopic dermatitis (AD) had no approved systemic therapies beyond off-label cyclosporine and oral corticosteroids, both limited by toxicity and rebound flares. The discovery that type 2 inflammation driven by IL-4 and IL-13 was central to AD pathogenesis opened a new therapeutic frontier. Cyclosporine, while effective short-term, demonstrated significant nephrotoxicity and hypertension with prolonged use, underscoring the urgent need for targeted agents. The conceptual shift from AD as a purely barrier defect to an immune-mediated disease laid the groundwork for biologic development.
Landmark RCTs and pivotal trials that established the evidence base
Dupilumab, a monoclonal antibody blocking IL-4 receptor alpha (and thus both IL-4 and IL-13 signaling), transformed AD management. The SOLO 1 and SOLO 2 trials demonstrated that dupilumab achieved IGA 0/1 in 36-38% of patients versus 8-10% with placebo at week 16, with rapid and sustained itch reduction. The CAFE trial confirmed efficacy in patients who had failed or were intolerant to cyclosporine, establishing dupilumab as a viable option for the most refractory cases. FDA approval in 2017 marked the first biologic approved for AD, validating decades of immunological research and giving clinicians their first targeted systemic therapy.
Follow-up studies, subgroup analyses, and real-world validation
The JAK inhibitor class rapidly expanded the oral treatment landscape for AD. Baricitinib (BREEZE-AD1/AD2), upadacitinib (Measure Up 1/2), and abrocitinib (JADE MONO-1/MONO-2) each demonstrated robust efficacy, with upadacitinib and abrocitinib showing particularly rapid itch relief within days of initiation. The head-to-head JADE DARE trial showed abrocitinib 200mg was non-inferior to dupilumab for itch response at week 2, though dupilumab showed numerically better skin clearance at later time points. Tralokinumab, targeting IL-13 alone (ECZTRA 1-3), provided another injectable option with a distinct mechanism, further personalizing treatment approaches. These agents collectively transformed AD from a condition with one systemic option to one with multiple mechanistically distinct therapies.
Integration into clinical practice guidelines and recommendations
The AAD 2024 guidelines and European (ETFAD/EDF) consensus position dupilumab as first-line systemic therapy for moderate-to-severe AD in adults, with JAK inhibitors as alternatives particularly when rapid onset is needed or injection aversion exists. The NICE technology appraisals (TA681, TA814, TA834) have approved dupilumab, baricitinib, upadacitinib, abrocitinib, and tralokinumab with specific positioning. European guidelines emphasize shared decision-making regarding JAK inhibitor cardiovascular and thromboembolic risk warnings. A stepwise approach remains standard: optimize topical therapy first, then systemic therapy guided by patient phenotype, comorbidities, and preferences.
AAD Guidelines for Management of Atopic Dermatitis with Systemic Therapies
Dupilumab recommended as first-line biologic; JAK inhibitors as alternative systemic therapy with cardiovascular risk counseling
European Task Force on Atopic Dermatitis (ETFAD)/EDF Position Paper
Systemic therapy indicated for moderate-to-severe AD; treatment selection guided by disease phenotype, comorbidities, and patient preference
NICE Technology Appraisal TA681
Dupilumab recommended for moderate-to-severe AD when conventional systemic therapy is inadequate or inappropriate
Now
Current standard of care and ongoing research directions
AD treatment in 2025-2026 features a rich systemic pipeline with ongoing mechanistic diversification. Lebrikizumab (anti-IL-13) gained recent approvals, and nemolizumab (anti-IL-31 for itch) represents a novel pruritus-targeted approach. Topical JAK inhibitors (ruxolitinib) bridge the gap between topical and systemic therapy. Pediatric indications have expanded, with dupilumab approved down to 6 months of age. Key research frontiers include biomarker-guided therapy selection (blood eosinophils, IgE, TARC levels), combination strategies, and understanding whether early aggressive intervention can modify the atopic march. The field has evolved from managing a chronic nuisance to treating a serious systemic inflammatory disease.
How do JAK inhibitors compare to dupilumab for atopic dermatitis?+
JAK inhibitors (upadacitinib, abrocitinib) offer faster itch relief (days vs weeks) and oral dosing. Dupilumab has a more favorable long-term safety profile with fewer laboratory monitoring requirements. Head-to-head data (JADE DARE) shows comparable efficacy, with choice guided by patient preference, speed requirements, and risk tolerance.
What are the key safety concerns with JAK inhibitors in AD?+
Based on the ORAL Surveillance trial in RA (higher-risk population), JAK inhibitors carry FDA boxed warnings for cardiovascular events, malignancy, thrombosis, and serious infections. In the younger, healthier AD population, real-world data suggest lower absolute risks, but cardiovascular risk factor screening before initiation and ongoing monitoring are recommended.
When should systemic therapy be initiated in atopic dermatitis?+
Systemic therapy is indicated when optimized topical therapy (including potent topical corticosteroids and calcineurin inhibitors) fails to adequately control disease, typically at moderate-to-severe severity (EASI >16 or DLQI >10). Earlier systemic initiation is increasingly advocated to prevent the cumulative disease burden and quality-of-life impact of poorly controlled AD.
Is dupilumab safe in children with atopic dermatitis?+
Dupilumab has been extensively studied and approved for AD in children as young as 6 months. Pediatric trial data (LIBERTY AD PEDS) show efficacy and safety comparable to adults, with conjunctivitis (10-15%) being the most notable side effect. It has become the first-line systemic option for pediatric moderate-to-severe AD.
